Juan Antonio Carrillo

Summary

Affiliation: University of Extremadura
Country: Spain

Publications

  1. ncbi request reprint [Pharmacokinetic process: does the site of drug action? Excretion of drugs]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 34:24-31. 2011
  2. ncbi request reprint [Genetic biomarkers and personalized medicine: application in cardiovascular pharmacology]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 36:41-50. 2013
  3. ncbi request reprint [Drug interactions and clinical relevance: it all began with cheese]
    Juan Antonio Carrillo Norte
    Departemento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:8-18. 2012
  4. ncbi request reprint [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:10-9. 2012
  5. ncbi request reprint [The pharmacodynamic process: is the drug producing the required effect?]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:8-15. 2012
  6. pmc CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study
    Carmen San Jose
    Merida Hospital, Research Unit, 06008 Merida, Spain
    BMC Cancer 10:463. 2010
  7. ncbi request reprint Clinically significant pharmacokinetic interactions between dietary caffeine and medications
    J A Carrillo
    Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, Spain
    Clin Pharmacokinet 39:127-53. 2000
  8. ncbi request reprint [The pharmacokinetic process: is the drug getting to its site of action?: Drug distribution (ADME)]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:42-8. 2010
  9. ncbi request reprint [Volume of distribution of drugs: an apparent data in pharmacology]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:48-52. 2010
  10. ncbi request reprint [Anatomophysiological bases of drug administration. Dosage forms and routes of administration]
    Juan Antonio Carillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:28-32, 35-9. 2010

Collaborators

Detail Information

Publications27

  1. ncbi request reprint [Pharmacokinetic process: does the site of drug action? Excretion of drugs]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 34:24-31. 2011
    ..However, if the drug or an active metabolite is excreted unchanged via the kidneys, changes in renal function (i.e. chronic renal failure) will influence its elimination. Therefore, dose adjustment of the drug should be recommended...
  2. ncbi request reprint [Genetic biomarkers and personalized medicine: application in cardiovascular pharmacology]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 36:41-50. 2013
    ..It may help clinicians to individualize dosing drug regimen, maximize drug efficacy and enhance drug safety with certain drugs and populations at risk...
  3. ncbi request reprint [Drug interactions and clinical relevance: it all began with cheese]
    Juan Antonio Carrillo Norte
    Departemento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:8-18. 2012
    ..The most obvious interactions are those producing altered pharmacokinetic of drugs with a low therapeutic index (oral anticoagulants, antidiabetic drugs, digoxin, benzodiazepines and immunosuppressant and cytotoxic drugs)...
  4. ncbi request reprint [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:10-9. 2012
    ....
  5. ncbi request reprint [The pharmacodynamic process: is the drug producing the required effect?]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 35:8-15. 2012
    ..Another is that drugs do not create effect, but instead modulate functions. The features of agonists and blockade by antagonists are also described...
  6. pmc CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study
    Carmen San Jose
    Merida Hospital, Research Unit, 06008 Merida, Spain
    BMC Cancer 10:463. 2010
    ..The present work was undertaken to ascertain the role of CYP1A1 gene polymorphisms and their interaction with tobacco smoking in the development of the disease in this location...
  7. ncbi request reprint Clinically significant pharmacokinetic interactions between dietary caffeine and medications
    J A Carrillo
    Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, Spain
    Clin Pharmacokinet 39:127-53. 2000
    ..Finally, caffeine is a useful and reliable probe drug for the assessment of CYP1A2 activity, which is of considerable interest for metabolic studies in human populations...
  8. ncbi request reprint [The pharmacokinetic process: is the drug getting to its site of action?: Drug distribution (ADME)]
    Juan Antonio Carrillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:42-8. 2010
    ..15 L/kg). This is because if the drug is widely distributed to the body tissues, then even large increases in the amount of unbound drug in the plasma will be unimportant...
  9. ncbi request reprint [Volume of distribution of drugs: an apparent data in pharmacology]
    Juan Antonio Carrillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:48-52. 2010
    ....
  10. ncbi request reprint [Anatomophysiological bases of drug administration. Dosage forms and routes of administration]
    Juan Antonio Carillo Norte
    Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:28-32, 35-9. 2010
    ..When there is no contraindication, oral route of drug administration is of choice and most frequently used as a physiological pathway of drug intake...
  11. ncbi request reprint [The pharmacokinetic process: is the drug getting to its site of action?: Drug metabolism]
    Juan Antonio Carrillo Norte
    Profesor Titular de Universidad, Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina de Badajoz, Universidad de Extremadura
    Rev Enferm 34:52-60. 2011
    ..It may regulate drug metabolism through modulation (induction or inhibition) of the activities of CYPs and hence, it may provoke the occurrence of severe adverse drug reactions...
  12. ncbi request reprint [The pharmacokinetic process: is the drug getting to its site of action? Drug absorption]
    Juan Antonio Carillo Norte
    Area de Farmacología Clinica, Departamento de Terapéutica Médico Quirúrgica, Facultad de Medicina, Universidad de Extremadura
    Rev Enferm 33:58-66. 2010
    ..However, they may cause therapeutic failure due to low steady-state concentration of the drug during long-term treatment...
  13. ncbi request reprint Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine
    Juan Antonio Carrillo
    Department of Pharmacology and Psychiatry, Extremadura University School of Medicine, Badajoz, Spain
    J Clin Psychopharmacol 23:119-27. 2003
    ..The performance of a simple caffeine test may assist in individualization of the olanzapine dosage...
  14. doi request reprint Haplotypes in the 5'-untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism
    Guillermo Gervasini
    Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
    Environ Mol Mutagen 54:124-32. 2013
    ..Several CYP1A2 haplotypes and diplotypes containing the -2467delT variant were associated with lower lung cancer risk; however, they did not correlate with significant changes in CYP1A2 metabolic activity toward caffeine...
  15. ncbi request reprint Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer
    Guillermo Gervasini
    Department of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
    Cancer 107:2850-7. 2006
    ..P-gp is expressed in the lung, where it has been suggested to transport these compounds from the interstitium into the lumen...
  16. pmc The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, Medical School and Clinical Pharmacology Unit, Infanta Cristina University Hospital, University of Extremadura, E 06071 Badajoz, Spain
    Br J Clin Pharmacol 62:177-86. 2006
    ..To determine the effect of gender and the genetic polymorphisms of CYP2J2, CYP3A4, CYP3A5 and MDR1 on the urinary excretion of the H(1) antihistamine ebastine in healthy subjects...
  17. doi request reprint GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area
    Guillermo Gervasini
    Department of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
    Nutr Cancer 62:750-8. 2010
    ..These results warrant further investigations to confirm the observed associations...
  18. ncbi request reprint Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, Extremadura University School of Medicine, E 06071 Badajoz, Spain
    Clin Chem 49:2088-91. 2003
  19. doi request reprint Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy
    Guillermo Gervasini
    Department of Medical and Surgical Therapeutics, Division of Clinical Pharmacology, Medical School, University of Extremadura, 06071 Badajoz, Spain
    Eur J Clin Pharmacol 66:755-74. 2010
    ..g. antidepressants in older people)...
  20. ncbi request reprint Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, Medical School, and Clinical Pharmacology Unit, Infanta Cristina University Hospital, University of Extremadura, Badajoz, Spain
    Ther Drug Monit 27:819-21. 2005
    ..These findings suggest that dose requirements for drugs metabolized by CYP3A and certain allele-disease association studies in white populations could show discrepancies in Spaniards...
  21. doi request reprint Influence of dopamine polymorphisms on the risk for anorexia nervosa and associated psychopathological features
    Guillermo Gervasini
    Department of Medical and Surgical Therapeutics, Division of Clinical Pharmacology, Medical School, University of Extremadura, Badajoz, Spain
    J Clin Psychopharmacol 33:551-5. 2013
    ..05). The results show that certain genetic alterations in the dopamine pathways are able to modify the risk for AN as well as modulate psychopathological features that are often coupled to this disorder...
  22. ncbi request reprint Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds
    Guillermo Gervasini
    Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, Spain
    Clin Pharmacokinet 43:693-706. 2004
    ....
  23. ncbi request reprint Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions
    Tomas Morera
    Drug Surveillance Center of Extremadura, Department of Pharmacology and Psychiatry and Clinical Pharmacology Unit, Infanta Cristina University Hospital, Medical School, University of Extremadura, Badajoz, Spain
    Basic Clin Pharmacol Toxicol 96:289-94. 2005
    ..New systems developed to improve prescribing, including a new method based on personal contact between Drug Surveillance Centres and general practitioners, are discussed...
  24. ncbi request reprint Xanthine oxidase activity is influenced by environmental factors in Ethiopians
    Eleni Aklillu
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Eur J Clin Pharmacol 59:533-6. 2003
    ..To investigate xanthine oxidase (XO) polymorphism in Ethiopians and influence of environmental factors, smoking habit and gender-related differences on enzyme activity among Ethiopians living in Ethiopia or Sweden...
  25. ncbi request reprint Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
    Eleni Aklillu
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Mol Pharmacol 64:659-69. 2003
    ....
  26. ncbi request reprint Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
    Magnus Christensen
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Clin Pharmacol Ther 71:141-52. 2002
    ....
  27. ncbi request reprint Thrombocytopenia and fatality associated with olanzapine
    Juan Antonio Carrillo
    Eur J Clin Pharmacol 60:295-6. 2004